{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-032227","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2024-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.824928+00:00","generated_at":"2026-05-31T19:59:35.404500+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Champions Oncology reports FY2024 revenue down 7% to $50.2M; Q4 adjusted EBITDA turns positive $884K","bullets":["Q4 revenue $14.0M (+7% YoY); Q4 adjusted EBITDA income $884K vs loss $922K prior year.","FY2024 revenue $50.2M (-7% YoY); FY adjusted EBITDA loss $3.9M vs loss $1.3M prior year.","Q4 gross margin 48% (pharmacology services 49%); FY gross margin 41% vs 45% prior year.","Cash $2.6M, no debt; stock repurchase program paused; Corellia AI unit seeking external capital.","Q4 operating loss $190K narrowed from $2.5M prior year; cost-cutting measures improving bottom line."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-032227","json":"https://secwatch.observer/filing/0001628280-24-032227.json","markdown":"https://secwatch.observer/filing/0001628280-24-032227.md","text":"https://secwatch.observer/filing/0001628280-24-032227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828024032227/0001628280-24-032227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828024032227/csbr-20240718.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:59:35.404500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}